Effects of Amino Acid Formulation on Healthy Men Undergoing Unilateral Knee Immobilization
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Ontario
-
Hamilton, Ontario, Canada, L8S4K1
- McMaster Univeristy
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Generally healthy, non-smoking
- Willing and able to provide informed consent
- Men age 20-45 years
- BMI between 25 and 35 kg/m2
Exclusion Criteria:
- Smoker;
- Subject has any concurrent medical, orthopedic, or psychiatric condition that, in the opinion of the Investigator, would compromise his/her ability to comply with the study requirements;
- History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years;
- Significant orthopedic, cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder (requiring ongoing medical care), or metabolic/endocrine disorder (e.g., diabetes, high cholesterol, elevated fasting blood sugar) or other disease that would preclude oral protein supplement ingestion and/or assessment of safety and study objectives;
- Any cachexia-related condition (e.g., relating to cancer, tuberculosis or human immunodeficiency virus infection and acquired immune deficiency syndrome) or any genetic muscle diseases or disorders;
- Current illnesses which could interfere with the study (e.g. prolonged severe diarrhea, regurgitation, difficulty swallowing);
- Subject participated in a study of an investigational product less than 60 days or 5 half-lives of the investigational product, whichever is longer, before enrollment in this study;
- Hypersensitivity to any of the components of the test product;
- Excessive alcohol consumption (>21 units/week); (> 21 standard drinks/wk); e.g., 18oz glass of 5% beer - 1.5 standard drinks, a 750 mL bottle of 12% wine = 5 standard drinks.
- Known sensitivity or allergy to amino acids or any ingredient in the test formulations;
- Prior gastrointestinal bypass surgery (Lapband, etc.), irritable bowel disease or irritable bowel syndrome;
- History of bleeding diathesis, platelet or coagulation disorders, or antiplatelet/anticoagulation therapy (up to 81mg of baby aspirin per day taken as a prophylactic is permitted);
- Personal or family history of clotting disorder or deep vein thrombosis. Deep vein thrombosis is a serious, and potentially lethal, medical condition, therefore, it is imperative if you have personal or family history it is disclosed this to the research staff.
- Concomitant use of corticosteroids, testosterone replacement therapy (ingestion, injection, or transdermal), any anabolic steroid, creatine, whey protein supplements, casein or branched-chain amino acids (BCAAs) within 45 days prior to Screening;
- Contraindications to an MRI scan (e.g. subjects with non-removable ferromagnetic implants, pacemakers, aneurysm clips or other foreign bodies, or subjects with claustrophobic symptoms that would contraindicate an MRI scan).
- Hemoglobin <11.5mg/dl at Screening;
- Platelets <150,000/uL (150x109/L) at Screening.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Amino Acid
Subjects in this arm will receive amino acid supplementation (23.7g) 3 times daily for 28 days.
Amino acids will be provided in powder form to be dissolved in 8oz of water.
Participants will also undergo single-leg immobilization (Breg brace) for 7 days (days 8-15) during the 28 day study period.
|
23.7 g amino acid 3 times daily for 28 days
7 days of single leg immobilization; randomized to leg; knee brace will be worn in a fixed flexion position at 140°.
Andre navne:
|
|
Placebo komparator: Placebo
Subjects in this arm will receive placebo 3 times daily for 28 days.
Placebo will consist of 23.7g of excipient-matched placebo in water.
Participants will also undergo single-leg immobilization (Breg brace) for 7 days (days 8-15) during the 28 day study period.
|
7 days of single leg immobilization; randomized to leg; knee brace will be worn in a fixed flexion position at 140°.
Andre navne:
Excipient-matched placebo 3 times daily for 28 days
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in muscle atrophy
Tidsramme: day 0, day 8, day 15 and day 28
|
To determine the impact of an amino acid formulation on muscle atrophy after 7 days of amino acid supplementation followed by 7 days of single leg immobilization and 14 days of recovery post-immobilization muscle atrophy will be assessed utilizing percutaneous muscle biopsy to quantify fibre size in the vastus lateralis.
|
day 0, day 8, day 15 and day 28
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in muscle strength
Tidsramme: day 0, day 8, day 15 and day 28
|
Strength will be measured using a Biodex.
|
day 0, day 8, day 15 and day 28
|
|
Change in muscle size
Tidsramme: day 0, day 8, day 15 and day 28
|
Muscle size will be assessed via MRI.
|
day 0, day 8, day 15 and day 28
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 3365
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Muskelatrofi
-
NCT05638958Aktiv, ikke rekrutterendeEdentulous Alveolar Ridge Atrophy
-
NCT05282862RekrutteringEdentulous Alveolar Ridge Atrophy
-
NCT07104370RekrutteringEdentulous Alveolar Ridge Atrophy | Edentulous Alveolar Ridge
-
NCT05458271Aktiv, ikke rekrutterendeEdentulous Alveolar Ridge Atrophy | Blødt vævsforøgelse ved tandimplantater
-
NCT05500911AfsluttetEdentulous Alveolar Ridge Atrophy | Edentuous; Alveolær proces, atrofi
-
NCT07014527AfsluttetEdentulous Alveolar Ridge Atrophy | ATROFISK EDENTULØS KÆBE | Edentuous Maxilla | Edentulous Alveolar Ridge I Mandible
-
NCT07465198Ikke rekrutterer endnuMSA - Multiple System Atrophy | MSA
-
NCT05197816AfsluttetMSA - Multiple System Atrophy
-
NCT05696717Aktiv, ikke rekrutterendeMSA - Multiple System Atrophy | Symptomatisk neurogen ortostatisk hypotension
-
NCT05011773AfsluttetEpilepsi | Kronisk smerte | Parkinsons sygdom | MSA - Multiple System Atrophy
Kliniske forsøg med Amino Acid
-
NCT05935826RekrutteringNAFLD | Teenagers fedme | Hepatisk Steatose
-
NCT03715010AfsluttetGlucoseintolerance | Overvægtige | Præ-diabetes
-
NCT03717935AfsluttetFedme | Polycystisk ovariesyndrom | Hepatisk Steatose
-
NCT01215396AfsluttetPsykologiske fænomener: Central træthed
-
NCT01529281AfsluttetTrænings-induceret muskelskade
-
NCT05700695AfsluttetAkut-på-kronisk leversvigt | Hepatisk encefalopati
-
NCT04771104AfsluttetLevercirrhose | Hepatisk encefalopati | Søvnforstyrrelser
-
NCT04226586AfsluttetVækstsvigt | Ernæringsmæssig hæmning
-
NCT03908255Trukket tilbageLeversvigt | Hepatocellulært karcinom | Cirrhose